|By Business Wire||
|August 18, 2014 12:40 PM EDT||
Research and Markets (http://www.researchandmarkets.com/research/53xwbk/global) has announced the addition of the "Global Regenerative Medicines Market (Technology, Application and Geography) - Size, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering.
According to a new market research report titled, "Global Regenerative Medicine Market (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020). Small molecules and biologics segment holds prominent market share in the overall regenerative medicine technology market and is anticipated to grow at a CAGR of 18.9% during the forecast period.
Regenerative medicines have the ability to restore the lost functionality of tissues or organs, unlike conventional medicines, which are palliative. The immense potential of these medicines in repairing or regenerating diseased organs is the major reason for intensive focus on research and development in this field. The technologies implemented for these medicines utilize various cell types including stem cells. The advancements in nanotechnology and stem cells application would account for further progress of this novel field of medicine. The global regenerative medicine market is segmented based on technologies into small molecules and biologics, gene therapy and cell therapy.
Key Topics Covered:
CHAPTER 1. INTRODUCTION
CHAPTER 2. EXECUTIVE SUMMARY
CHAPTER 3. GLOBAL REGENERATIVE MEDICINES MARKET OVERVIEW
CHAPTER 4. GLOBAL REGENERATIVE MEDICINE MARKET BY TECHNOLOGIES
CHAPTER 5. GLOBAL REGENERATIVE MEDICINE MARKET BY APPLICATIONS
CHAPTER 6. GLOBAL REGENERATIVE MEDICINES MARKET BY GEOGRAPHY
CHAPTER 7. COMPANY PROFILES
- Advanced Cell Technology
- Athersys Inc.
- Cytori Therapeutics
- Kinetic Concepts
- Mesoblast Ltd.
- Shire pharmaceuticals
- Stem Cells
For more information visit http://www.researchandmarkets.com/research/53xwbk/global
The web app is agile. The REST API is agile. The testing and planning are agile. But alas, data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes that force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software organ...
Sep. 5, 2015 01:30 PM EDT Reads: 245
Sep. 5, 2015 01:15 PM EDT Reads: 182
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
Sep. 5, 2015 01:15 PM EDT Reads: 445
Sep. 5, 2015 01:00 PM EDT Reads: 151
Sep. 5, 2015 01:00 PM EDT Reads: 402
Sep. 5, 2015 01:00 PM EDT Reads: 182
Sep. 5, 2015 01:00 PM EDT Reads: 151
Sep. 5, 2015 12:45 PM EDT Reads: 211
Sep. 5, 2015 12:45 PM EDT Reads: 601
Sep. 5, 2015 12:30 PM EDT Reads: 319
Sep. 5, 2015 12:00 PM EDT Reads: 1,648
Sep. 5, 2015 12:00 PM EDT Reads: 261
Sep. 5, 2015 12:00 PM EDT Reads: 172
Sep. 5, 2015 11:45 AM EDT Reads: 260
Sep. 5, 2015 11:45 AM EDT Reads: 692